Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701
- None.
- None.
The recent announcement by Vetbiolix on the positive results of the Proof-of-Concept study for the VBX-1000 drug candidate, previously MIV-701, represents a significant milestone not only for the company but also for the pet health industry. The success of this study indicates the potential for VBX-1000 to meet a market need for innovative treatments in veterinary medicine, particularly for periodontal disease in dogs, which is a common ailment that can lead to further health complications if left untreated.
From a business perspective, the move by Medivir to out-license MIV-701 to Vetbiolix underscores a strategic approach to monetize their research and diversify risk. The financial structure of the deal, including both milestone payments and future royalties, presents a balanced opportunity for revenue generation while mitigating upfront development costs. This could potentially lead to a more stable and attractive financial outlook for Medivir, contributing positively to shareholder value.
Furthermore, the partnership between Medivir and Vetbiolix exemplifies the growing trend of collaboration between human and veterinary pharmaceutical sectors. Such alliances can spur innovation and open up additional revenue streams for companies like Medivir that are traditionally focused on human therapeutics.
The successful Proof-of-Concept study for VBX-1000, which showed a reduction in the biomarker for bone degradation (CTX1) in dogs, could indicate a breakthrough in veterinary medicine. The cathepsin-K inhibitors like VBX-1000 represent a novel class of drugs in veterinary care. As pet ownership increases and owners are willing to spend more on pet healthcare, the demand for advanced treatments could see substantial growth.
Furthermore, the fact that Medivir is involved and has a stake in the success of VBX-1000 through milestone and royalty payments reflects the potential high market expectations for this drug. Should Vetbiolix manage to navigate the regulatory landscape effectively and VBX-1000 enters the market, it is poised to capture a significant share given the current lack of specific treatments for periodontal disease in pets.
Finally, positive clinical advancements in the pet health sector can often have parallel implications in human medicine. Insights gained from this study may inform future developments in Medivir's core focus area of cancer treatment, which could have a longer-term strategic impact on the company's research direction and portfolio expansion.
VBX-1000 (MIV-701) is the first specific cathepsin-K inhibitor, for the treatment of periodontal disease in dogs. During the early development of a selective cathepsin-K inhibitor, MIV-701 was discovered to have properties suitable for non-human animal use and it was out-licensed to Vetbiolix in 2019 to explore clinical utility in non-human animal.
In the study conducted by Vetbiolix, the drug was well tolerated and the primary efficacy endpoint was met, achieving a statistically significant reduction of the plasma biomarker for bone degradation (CTX1). Vetbiolix is now working with experts in the field to set up a regulatory Pilot clinical study to further strengthen the demonstration of the effects of VBX-1000 (MIV-701) in a double blind, randomized, placebo-controlled clinical trial in dogs.
As part of the agreement with Vetbiolix, Medivir is entitled to minor development and regulatory milestone payments with value upside potential coming from future royalty payments on net sales and/or share of partnering payments received by Vetbiolix in case of future partnering transactions with VBX-1000.
- "Partnering and collaborations are important parts of Medivir's business model to accelerate the development of all assets and reduce financial risk. MIV-701 is another example of the company's ability and track-record in out-licensing to generate additional value for shareholders. The positive results of the Proof-of-Concept study are also a testament to the quality of research performed by Medivir and add yet another molecule to the number of candidates that have been shown to provide clinical benefit," says Jens Lindberg, Chief Executive Officer at Medivir.
For additional information, please contact;
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100.
E-mail: magnus.christensen@medivir.com
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
About Vetbiolix
Vetbiolix develops innovative products for the treatment and prevention of diseases affecting pets. Vetbiolix has built a unique pipeline of First-in-class small molecules in-licensed (exclusive and worldwide license) from Human Biotech worldwide which will answer to veterinary unmet medical needs in periodontitis, osteoarthritis and gut motility disorders. Vetbiolix focuses exclusively on clinical developments of its drug candidates: the company invests on (i) clinical proof of concept studies, (ii) CMC-Pharmaceutical developments, (iii) regulatory Pilot clinical studies and (iv) regulatory Pivotal clinical studies. Revenue generation of the company will be based on out-licensing and/or co-developments deals with the Veterinary Pharmaceutical Industry www.vetbiolix.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/medivirs-partner-vetbiolix-announces-positive-results-from-proof-of-concept-study-with-vbx-1000-previously-known-as-miv-701-302116699.html
SOURCE Medivir
FAQ
What are the positive results reported by Vetbiolix regarding VBX-1000 (MIV-701)?
What is VBX-1000 (MIV-701) and its role in the study?
What benefits does Medivir stand to gain from the partnership with Vetbiolix?
Who is Jens Lindberg and what is his role in Medivir?
